불안신경증과 알코올남용·의존 환자에서 Tofisopam의 항불안 및 항우울 효과 검증 = Antianxiety and Antidepressant Effects of Tofisopam in Anxiety Neurosis and Alcohol Abuse or Dependence

다국어 초록 (Multilingual Abstract)

The study aims at evaluating antianxiety and antidepressant effects of tofisopam, a benzodiazepine-related chemical substance with some variations in its nitrogen number and positions. The study subjects were 27 adult outpatients, namely, 11 anxiety neurosis patients(M 6, F 5) and 16 alcohol abuse or alcohol dependence patients(M 13, F 3), diagnosed according to DSM-IV. Tofisopam, doses ranging 100-150mg per day, was administered to each patient in an open clinical trial, over a period of 6-8 week.
Each patient was administered with Hamilton Anxiety Scale(HAS) and Hamilton Depression Scale(HDS) twice, before the initiation of tofisopam admininistration and at the completion of 6-8 weeks of the medication administration, to assess the degree and extent of improvements of anxiety and depression symptoms. The following results were obtained from the study：
(1) Tofisopam showed noticeably significant antianxiety effects and less significant antidepressant effects.
(2) There were no clinically observable or reported untoward CNS effects(e.g. drowsiness, impaired memory, disturbance in attention, etc.) by tofisopam.
(3) The more significant improvements among the anxiety symptom clusters were physical(musculomotor and sensory) and autonomic nervous system symptoms.
(4) During and immediately after the completion of 6-8 weeks of tofisopam adminstration, alcoholic patients reported
of significantly reduced or extinct alcohol cravings. However,
it remains to be carefully evaluated whether anticraving effects of tofisopam is transient, long lasting, or psychogenic, etc.
The study results warrants further careful revalidations by use of a longitudinal double-blind crossover design and on a large number of patients.

목차 (Table of Contents)

• 서 론
• 연구대상 및 방법
• 결 과
• 고 찰
• 결 론